Severe manifestation of Rauch‐Azzarello syndrome associated with biallelic deletion of CTNND2
Clinical Genetics · 2024
DOI: 10.1111/cge.14532 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Genetics, 2024. Verfasst von Melissa Pauly und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Delta Catenin, Neurodevelopmental Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Interdisziplinäres Zentrum für Klinische Forschung (IZKF), Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, German Federal Ministry of Education and Research (BMBF).
Abstract (Originalsprache)
CTNND2 encodes δ‐catenin, a component of an adherens junction complex, and plays an important role in neuronal structure and function. To date, only heterozygous loss‐of‐function CTNND2 variants have been associated with mild neurodevelopmental delay and behavioral anomalies, a condition, which we named Rauch‐Azzarello syndrome. Here, we report three siblings of a consanguineous family of Syrian descent with a homozygous deletion encompassing the last 19 exons of CTNND2 predicted to disrupt the transcript. All presented with severe neurodevelopmental delay with absent speech, profound motor delay, stereotypic behavior, microcephaly, short stature, muscular hypotonia with lower limb hypertonia, and variable eye anomalies. The parents and the fourth sibling were heterozygous carriers of the deletion and exhibited mild neurodevelopmental impairment resembling that of the previously described heterozygous individuals. The present study unveils a severe manifestation of CTNND2 ‐associated Rauch‐Azzarello syndrome attributed to biallelic loss‐of‐function aberrations, clinically distinct from the already described mild presentation of heterozygous individuals. Furthermore, we demonstrate novel clinical features in homozygous individuals that have not been reported in heterozygous cases to date.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Human Genetics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Children's Clinic, Klinikum Bayreuth GmbH, Bayreuth, Germany.
- MCO, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Centre for Rare Diseases Erlangen (ZSEER), Universitätsklinikum Erlangen, Erlangen, Germany.
Förderung
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF), Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- German Federal Ministry of Education and Research (BMBF)
Zitieren
APA
Pauly, M., Krumbiegel, M., Trumpp, S., Braig, S., Rupprecht, T., Kraus, C., Uebe, S., Reis, A., & Vasileiou, G. (2024). Severe manifestation of Rauch‐Azzarello syndrome associated with biallelic deletion of CTNND2. Clinical Genetics. https://doi.org/10.1111/cge.14532
Vancouver
Pauly M, Krumbiegel M, Trumpp S, Braig S, Rupprecht T, Kraus C, et al. Severe manifestation of Rauch‐Azzarello syndrome associated with biallelic deletion of CTNND2. Clinical Genetics. 2024. doi:10.1111/cge.14532
BibTeX
@article{Pauly2024,
author = {Pauly, Melissa and Krumbiegel, Mandy and Trumpp, Sandra and Braig, Sonja and Rupprecht, Thomas and Kraus, Cornelia and Uebe, Steffen and Reis, André and Vasileiou, Georgia},
title = {Severe manifestation of Rauch‐Azzarello syndrome associated with biallelic deletion of CTNND2},
journal = {Clinical Genetics},
year = {2024},
doi = {10.1111/cge.14532}
}
EUVIMED